Imcyse SA

Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis 

Imcyse joins CLAIMS, a European Health Initiative Project to Make Data-Driven Precision Medicine a Reality for Patients with Multiple Sclerosis

Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098 for Type 1 Diabetes

Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of ImotopeTM IMCY-0141 for Multiple Sclerosis

Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference

Imcyse SA: Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study

Imcyse Appoints Gene Mack, MBA as Chief Financial Officer

Imcyse nomme un nouveau Conseil consultatif scientifique et ouvre de nouveaux laboratoires pour permettre la prochaine phase de croissance.

Imcyse appoints new Scientific Advisory Board and opens new laboratories for next phase of growth

Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round – Pfizer Joins as Newest Shareholder

Imcyse Enters into Research Collaboration and License Agreement for its ImotopeTM Technology with Pfizer in Rheumatoid Arthritis

Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes

Imcyse scelle avec Pfizer un accord de collaboration de recherche et de licence portant sur sa technologie Imotope(TM) dans le domaine de la polyarthrite rhumatoïde

Imcyse annonce le lancement de l’étude de phase 2 IMPACT qui cible des patients récemment atteints de diabète de type 1, et qui est financée à hauteur de 6 millions d’euros pas la Région Wallonne

Imcyse SA: Imcyse annonce la nomination de Denis Bedoret au poste de Chief Executive Officer (CEO)

Imcyse Announces the Appointment of Denis Bedoret as Chief Executive Officer

Imcyse SA: Imcyse se voit octroyer une subvention de la Région wallonne pour une étude sur les troubles du spectre de la neuromyélite optique

Imcyse Awarded Subsidy from the Walloon Region for Neuromyelitis Optica Spectrum Disorder Study

Imcyse rejoint le consortium INNODIA dans le cadre du projet IMI contre le diabète de type 1

Imcyse Joins Type 1 Diabetes IMI Consortium INNODIA

Imcyse to present late-breaking abstract of its ImotopeTM-based antigen-specific immunotherapy for autoimmune diseases at ASIT 2020

Imcyse to present first-in-human phase 1b study results in type 1 diabetes at EASD 2019